Bristol Myers's most recent trend suggests a bearish bias. One trading opportunity on Bristol Myers is a Bear Call Spread using a strike $57.50 short call and a strike $62.50 long call offers a potential 16.01% return on risk over the next 37 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $57.50 by expiration. The full premium credit of $0.69 would be kept by the premium seller. The risk of $4.31 would be incurred if the stock rose above the $62.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Bristol Myers is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Bristol Myers is bearish.
The RSI indicator is at 56.77 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Bristol Myers
Why Johnson & Johnson is a More Attractive Stock Than its Rivals
Thu, 16 Jan 2014 23:33:00 GMT
Motley Fool – Johnson & Johnson is much cheaper than Bristol-Myers Squibb, and is performing better than Merck. That's what makes it the most attractive large-cap health care stock your money can buy.
Squawking mixed metaphors, the Pats, Fink on bonds
Thu, 16 Jan 2014 21:22:05 GMT
CNBC – This is Talking Squawk, the official “Squawk Box” blog, providing tidbits, insights and sarcastic reflections.
Davos, IMF Outlook, China GDP, Microsoft: Week Ahead Jan. 18-25
Thu, 16 Jan 2014 21:11:37 GMT
Bloomberg – The World Economic Forum begins in Davos, Switzerland, with more than 1,600 executives and policy makers attending, including Japanese Prime Minister Shinzo Abe and Brazilian President Dilma Rousseff.
J&J to sell slow-growing diagnostics unit to Carlyle
Thu, 16 Jan 2014 19:19:30 GMT
What Does This New Diabetes Drug Mean for AstraZeneca and Bristol-Myers Squibb?
Thu, 16 Jan 2014 19:16:29 GMT
Motley Fool – Bristol-Myers Squibb and AstraZeneca received FDA approval for their jointly developed diabetes drug Farxiga, but several post-market studies must be conducted.
Related Posts
Also on Market Tamer…
Follow Us on Facebook